XOMA Stock Analysis: Buy, Sell, or Hold?
XOMA - XOMA Royalty Corporation Common Stock
$40.17
-4.05 (-9.16%)
▼
5d:
-8.39%
30d:
-3.81%
90d:
+9.34%
HOLD
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 12, 2026
9d
Get Alerted When XOMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: XOMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: XOMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: XOMA is currently trading at $40.17, which is considered oversold relative to its 30-day fair value range of $41.69 to $44.26. From a valuation perspective, the stock is trading at a discount (Forward PE: -803.4) compared to its historical average (44.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XOMA is in a strong uptrend. The price is currently testing key support at $39.77. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.2% recently.
Market Sentiment: XOMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XOMA is in a strong uptrend. The price is currently testing key support at $39.77. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.2% recently.
Market Sentiment: XOMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$41.69 -
$44.26
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.2%)
- NEUTRAL: Near Wall St target ($39.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -8.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$41.69 -
$44.26
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$39.77
Resistance Level
$45.22
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-803.40
Wall Street Target
$39.00
(-2.9%)
Revenue Growth (YoY)
-22.6%
Earnings Growth (YoY)
207.9%
Profit Margin
69.6%
PE vs Historical
-803.4 vs 44.1
CHEAP
Share & Embed Analysis
Last updated: August 02, 2026 6:23 PM ET
Data refreshes hourly during market hours. Next update: 7:23 PM
Data refreshes hourly during market hours. Next update: 7:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XOMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 59 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 54 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 56 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 HOLD |
